Ryan Haumschild

1 week ago | ajmc.com | Ryan Haumschild |Eric Tichy

Author(s):,Panelists discuss how biosimilars for adalimumab have faced unique challenges in the prescription benefit space compared with earlier oncology biosimilars, highlighting the importance of interchangeability designation, advance planning, and stakeholder education when implementing biosimilar adoption strategies.

Jan 17, 2025 | businessandamerica.com | Ryan Haumschild

Video content above is prompted by the following:With several abstracts at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024 studying bispecific therapies in combination with conventional chemotherapy regimens, what factors should clinicians consider when deciding between monotherapy and combination approaches for bispecifics in FL and DLBCL? Do you see combination therapies with bispecifics as more viable in certain subtypes of B-cell lymphoma compared with others?

Jan 17, 2025 | ajmc.com | Ryan Haumschild

OpinionVideoJanuary 17, 2025Author(s):,Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi)trials in mantle cell lymphoma (MCL) are addressing unmet needs by providing novel therapeutic options, and explore how the integration of these therapies into current chronic lymphocytic leukemia (CLL) and MCL treatment guidelines could reshape management strategies, with consideration given to factors such as efficacy, safety, and patient access.

Jan 15, 2025 | businessandamerica.com | Ryan Haumschild

Video content above is prompted by the following:McMichael: In which patients do you treat AA vs use observation? Is there a scoring system that you use? Source link

Jan 15, 2025 | businessandamerica.com | Ryan Haumschild

Video content above is prompted by the following:Ungar: Which key factors influence your choice of initial therapy for patients with AA? Which drug classes do payers initially require in patients recently diagnosed with AA? Which therapies have the highest success rate? Which therapies have the lowest success rate? Source link